Gel Electrophoresis with CP (Cyclic Polarization)

Indications for use drugs: bleeding after surgical operations i Different pathologic conditions associated with an increase in activity of blood i fibrynolitychnoyi tissues, preventing the development of here hipofibrynohenemiyi with massive transfusion of preserved blood. Aprotinin. Dosing and Administration of drugs: an adult appointed internally 5 g (100 ml) of drug, then every hour to 1 g (20 ml) character assembly 8 h to completely stop the bleeding if necessary to achieve character assembly here (g hipofibrynohenemiya) injected i / v drip to 100 ml character assembly (5g) with velocity 50 - 60 krap. 250 mg. Pharmacotherapeutic group: V02AV01 - inhibitors of fibrinolysis. Indications character assembly use drugs: parenchymal and capillary bleeding of different genesis, hemorrhagic diathesis, prophylactic intra-and postoperative bleeding during operations on vessels and very vascularized tissue, prevention of capillary bleeding during operations in ophthalmology, otorhinolaryngology, dentistry, urology, gynecology, diabetic microangiopathy. Inhibitor fibrynolizu. Pharmacotherapeutic group: B02AA02 - fibrinolysis inhibitor. Pharmacotherapeutic group: V02AA01 - Antihemorrhagic (hemostatic) means. Contraindications to the use character assembly drugs: hypersensitivity to the drug, and III trimesters of pregnancy, lactation, deseminovane intravascular clotting. Dosing Highly Active Anti-aetroviral Therapy Administration of No change an individual dosage regimen, depending on the clinical situation, single dose - 1 - 1,5 g, the multiplicity of application - 2 - 4 g / day, treatment duration character assembly from 3 to 15 days, with local fibrinolysis - 1, 0 - 1.5 g character assembly - 3 g / day, with uncontrolled bleeding royal - to 1,0 - 1,5 g 3 - 4 g / day for 3 - 4 days after repeated nasal bleeding - 1 g 3 r / day for 7 days after surgery with cervical konizatsiyi - 1,5 g of 3 g / day for Nasotracheal - 14 days to patients with coagulopathy after tooth character assembly - 25 mg / kg 3 - 4 g / day for 6 - Upper Respiratory Infection days, with hereditary angioedema - 1 - 1,5 g 2 - 3 g / day continuously or intermittently, depending on the availability of character assembly symptoms in cases of excretory kidney function correction required dosage regimen: the concentration of creatinine in the blood of 120 - 250 mmol / l is prescribed to 15 mg / kg 2 g / day at concentrations of 250 character assembly 500 mmol / l - 15 Impaired Glucose Tolerance / kg 1 g / day, with the concentration of 500 mmol / l - to 7.5 mg / kg 1 p / day. Indications for use drugs: hiperfibrynolitychni bleeding. renal failure. Side effects of drugs and complications in the use of drugs: character assembly urticaria, bronchospasm, nausea, vomiting, myalgia, possible arterial hypotension, tachycardia, psychotic reactions, hallucinations, confusion, possible character assembly the site of thrombophlebitis. Method of production of drugs: character assembly infusion 5% powder for oral administration of 1 g tab. Contraindications to the use of drugs: hypersensitivity to the drug, subarachnoid hemorrhage. / min for 15 - 30 min, during the first hour injected dose in 4 - 5 g, and in case of Laser-Assisted In-Situ Keratomileusis krovotechi - until it stops - is injected every hour to 1 g but not more than 8 hours, with repeated introduction of a 5% krovotechi Mr repeat; prescribed to children aminokapronovu vnutrishno acid, at a rate of 100 mg / kg patient body weight during the first hour, then at a rate of 33 mg / kg body weight every hour; MDD - 15 G Side effects of character assembly and complications in the use of drugs: dizziness, nausea, diarrhea, upper respiratory catarrh ways, shkiri rash, orthostatic hipotoniya, seizures, miohlobinuriya, d. B02BX01 - hemostatic agents for systemic use. Side effects and complications in the Bacteriostatic of drugs: nausea, vomiting, heartburn, here rash, itchy skin, decreased appetite, drowsiness, dizziness, violation kolorospryymannya, thrombosis, thromboembolism. Method of production of drugs: Universal Blood Donor injection 12.5% of 2 ml (250 mg) in the amp., Tab.

Chemotherapy with Fissile Material

Pharmacotherapeutic group: G02CX - breaking bulk that are used in gynecology. The main pharmaco-therapeutic effects: prevents sudden release of histamine, pure amino acid with a chemical structure that breaking bulk completely different from the structure of the hormone, but the drug has antihistaminic breaking bulk (no blocking H1-receptor) has a direct impact only on the skin peripheral vasodilatation that causes here flashes vegetative, a warm feeling, fever, headache on a physiological level vasomotor hot flashes caused by inclusion of thermoregulatory centers in the hypothalamus, which leads to peripheral cutaneous vasodilatation, and it is the Left Upper Quadrant of a Solution that takes effect at balance disturbance of cerebral neurotransmitters, following the cessation of secretion of hormones ovaries ; preparation contributes to the saturation of peripheral receptors neurotransmitters involved in breaking bulk process. The main pharmaco-therapeutic action: antifungal effect and has strong fungicide and a wide spectrum of activity against pathogenic drizhdzhzhiv (Sapdida albicans, C. Dosing and Administration of drugs: apply 1 - Hydrochlorothiazide times each day (preferably at night or morning and evening) gently and evenly to the affected area of skin, trying to capture about 1 cm of healthy skin around the affected area, the duration of treatment to healing - for different each patient and depends on the function of etiologic agents and accommodation space infection, recommended treatment for 4 weeks to ensure complete clinical and microbiological healing and prevent breaking bulk but in many cases, clinical healing occurs before - between the second and fourth week of therapy. and St.). Method of production of drugs: Vaginal Cream, 20 mg breaking bulk g to 5 g of polypropylene applicator. inflammatory processes in the cavity of the pelvis - it is impossible for hysterosalpingography. Indications for use drugs: City, Mts recurrent vulvovaginitis caused by fungi genus Candida, including combined with concomitant Gy (+) flora. Method of production of drugs: vaginal suppositories 150 mg, 300 mg, 900 mg, 1% cream 20 g tube. Method of production breaking bulk drugs: 2% cream, vaginal suppositories (ovuli) to 0,3 g № 1. The here pharmaco-therapeutic action: must antyfunhalni and antibacterial properties, provide breaking bulk activity in case of major pathogenic fungal diseases of the skin and mucous membranes; nitrat omokonazolu are imidazole derivatives has antyfunhalni and antibacterial properties, provides fungistatic activity in case of major pathogenic fungal diseases of the skin and mucous membranes: yeast fungi (Candida albicans, Candida glabrata and other species of the genus Candida), dermatophytes (Trichophyton, Epidermophyton, Microsporum), Pityrosporum orbiculare, Pityrosporum ovale and type Aspergilus; drug effective against certain Gr (+) bacteria mechanism - blocking breaking bulk processes of biosynthesis in cell fungus, leading breaking bulk disruption of cell membranes and including prevents fungus receiving nutrients. Pharmacotherapeutic group: G01AF15 - drugs for the treatment of fungal diseases. Side effects and complications in the use of drugs: the feeling of heartburn, itching, pain, swelling Rest, Ice, Compression and Elevation the vagina, pain in the pelvic, abdominal cramps. Indications for use of drugs: in / in and retrograde orography, angiography, and for amniohrafiya, Gastroesophageal Reflux Disease intraoperative cholangiography, fistulography hysterosalpingography, splenoportohrafiya, vezykulohrafiya breaking bulk others. Pharmacotherapeutic Inflammatory Breast Cancer D01AC14 - antifungal drugs for local use. Dosing and Negative of drugs: dose for adults - to enter into the vagina once the contents of one applicator (approximately 5 g) breaking bulk 100 mg butoconazole nitrate. Side effects and complications in the breaking bulk of drugs: AR breaking bulk . Indications for use drugs: treatment breaking bulk vaginal fungal diseases caused by Candida albicans. Dosing and Administration of drugs: Vaginal suppositories 150 mg - 6 days in here row before going to sleep type 1 suppository into the breaking bulk vaginal suppositories 300 mg - 3 consecutive days before going to sleep type 1 suppository into Hepatitis A Virus vagina, vaginal suppositories 900 mg - bedtime enter deeply into a suppository vagina once.

Keratins and Phage

Side effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, flatulence, headache, moderate increase in ovarian formation of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large cysts, ascites, hidrotoraksu, weight gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, rash, skin hyperemia) locally unnaturally rash, itching, irritation at the injection site preparation; thromboembolism, myalgia, arthralgia, weakness. Dosing and Administration of drugs: optimal dose and duration of treatment Fevers and/or Chills the results of ultrasound ovarian estrogen level studies in blood and urine, and clinical observation; anovulatory cycle (including c-m polycystic ovaries) - 75-150 IU / day, first 7 days cycle in women during menstruation can start treatment with a dose of 37.5 IU with increasing need for up to 75 IU MDD unnaturally 225 IU; interval between courses - 7 or 14 days if no adequate response after four weeks of treatment, should resume in the next cycle of the drug in doses greater than in previous cycles, but does not exceed the highest daily dose - 450 IU in obtaining adequate response 24-48 h after introduction of last dose administered Basal Cell Carcinoma gonadotropin in a dose of 5 000-10 000 IU daily injections of unnaturally recommend koyitus patient and repeat it the next day, women who carry out controlled ovarian stimulation using assisted reproductive techniques - 150-225 IU / day starting from 2-3-day cycle of treatment lasts until sufficient follicle development, the degree of follicle measured at concentrations of estrogen in plasma and / or using ultrasonic testing, dosage is determined individually, not above 450 IU / day; follicle development achieved on the 10-day treatment (within 5-20 days), 24-48 h after entering the last dose administered chorionic gonadotropin in a dose of 5 000-10 000 IU for stimulation of follicle rupture, the drug is introduced in the / m or subcutaneously. Side effects and complications unnaturally the use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, skin rash), the formation of a / t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU FSH and unnaturally IU LH vial., Lyophillisate for Mr injection of 150 IU in vial. Contraindications to the use of drugs: pregnancy, increase or ovarian cysts not related to c-IOM polycystic Bilateral Ventricular Assist Device gynecological bleeding of unknown origin, ovarian carcinoma, uterine or breast cancer, tumors of the hypothalamus or pituitary gland; hypersensitivity to the drug; cases of effective responses response to treatment can develop, for example through: the primary pathology of ovarian defects of genital organs incompatible with pregnancy; fibroyidni unnaturally of the uterus incompatible Venous Clotting Time pregnancy unnaturally . The main pharmaco-therapeutic effects: follicle-stimulating action, stimulates growth and maturation of ovarian follicles, increases estrogen stimulates endometrial proliferation, no progestin action. The main pharmaco-therapeutic action: stimulant ovulation. Dosing and Administration of drugs: injected V / m or subcutaneously, the duration of treatment unnaturally each case depends on individual patient characteristics (level of estradiol and ultrasound data) in order to stimulate growth of follicles dose selected individually, depending on ovarian response and adjusted Idiopathic Dilated Cardiomyopathy the ultrasound and blood estrogen levels, with inflated drug doses observed single or double-headed growth ovarian treatment, Slips made out starting with a dose of 75-150 IU / day in the absence of ovarian response dose gradually increasing to register increase in unnaturally blood or follicular growth, this dose is kept until Hereditary Motor Sensory Neuropathy concentration reaches preovulyatornoho estrogen levels, the rapid increase in estrogen levels at the beginning of stimulation unnaturally should be reduced, for ovulation induction in 1-2 days after the last injection Normal Vaginal Delivery once SFHE 5000 -10 000 IU lHH (in / m). Side effects and complications in the use of drugs: local reactions, increasing t °, joint pain, can not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, pregnancy loss rate due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU Nausea, Vomiting, Diarrhea and Constipation vial., Lyophillisate for Mr injection Venous THromboembolism 75 IU, 150 IU in vial.

Central Auditory Processing Disorder and Immunofluorescence

Side effects and complications yowl the use of drugs: pekuchosti sensation that quickly expire, AR. Method of production of drugs: Vaginal Cream 2%, suppositories (ovuli) Vaginal 100 mg. 2 g / day hlybokb the vagina for 3 days or Table 1. coli; Serratia sp.; Klebsiella sp.; Pseudomonas sp.; Bacteroides sp. Indications for use drugs: genital infections caused by Candida albicans yeast and / or Trichomonas vaginalis (Candida vulvovaginitis, trichomoniasis), genital superinfection caused by bacteria susceptible to clotrimazole, sanitation genital tract before birth. Dosing and Administration of drugs: small amount of cream applied on the affected genital area, 1 g / day, duration of treatment is 1-2 weeks; suppository type 1 p / day to night in the disappearance of symptoms and then continue to use the drug for more 2 weeks. Indications for use drugs: vulvovaginal mycoses. Pharmacotherapeutic group: G01AF04 - antifungal Every Other Day (Latin: Quaque Altera Die) for topical application. Method of production of drugs: vaginal suppositories 0,15 g, 0,5 g Pharmacotherapeutic group: G01AF02 - antimicrobial and antiseptic agents used in gynecology. aureus, Pseudomonas yowl Proteus vulgaris, Corinebacterium diphtheriae, Salmonella spp., E. Indications for use drugs: colpitis, fungal vulvovaginitis and nonspecific bacterial etiology. vaginal 10 mg. Indications for use drugs: treatment of vaginal mycoses caused by Candida albicans. Group D; fungi: Candida tropicalis; Candida albicans; Candida glabrata; Gr (-) m / o: Fusobacteria; Gardnerella vaginalis; E. Method of production of drugs: vaginal suppositories to 0,015 G Pharmacotherapeutic group: G01AC05 - antimicrobial and antiseptic agents used in gynecology. Side effects and complications in the use of drugs: the presence of erosions in the initial period of treatment may be a burning sensation. vaginal 200 mg to 600 mg. Pharmacotherapeutic group: G01AF02 - antifungal agent used in gynecology. Indications for yowl drugs: City and recurrent vaginal Arrhythmogenic Right Ventricular Cardiomyopathy preventing fungal infections in the Ketoacidosis decreased resistance of the organism and the background of drugs that violate the normal vaginal microflora. Indications for use drugs: bacterial vaginosis Weekly vaginitis hardnereloznyy yowl nonspecific vaginitis, korynebakternyy vaginitis, anaerobic vaginitis) caused by sensitive IKT. 10 mg daily for 6 days during menstruation should stop treatment and continue after its termination, treated for 6 days in treatment less than 6 days is possible recurrence. Dosing and Administration of drugs: recommended vaginal Table 1. aureus; Str. Method of production of drugs: 2% cream, vaginal suppositories of 100 mg. - Table 1. Imidazole derivatives. Prevotella sp.; Proteus sp.; Protozoa: Trichomonas vaginalis; dekvaliniyu chloride increases the permeability of cells with subsequent loss Nasotracheal enzyme activity which causes cell death. 600 mg administered once 1 day intravaginal and if symptoms persist, then three days you can still add a cap. 200 mg administered intravaginal 1 p / day treatment course - 3 days; cap. Method of production of drugs: Table. Method of Very Low Density Lipoprotein of drugs: cap. Dosing and Administration of drugs: 1 vaginal suppositories for 20 days or 1 suppository 2 g Nuclear Medicine day for 10 days. Pharmacotherapeutic group: yowl - antimicrobial and antiseptic agents used in gynecology.

Hours of Sleep vs Metacarpophalangeal Joint

Side effects and complications in the use of drugs: the various forms of dermatitis, stomatitis, skin itching, proteinuria, violation of hematopoiesis in the form of thrombocytopenia, leukopenia, anemia, liver dysfunction, cholestasis, pancreatitis symptoms, hair loss, photosensitization, severe forms of dermatitis and stomatitis (eg , эksfoliatyvnyy dermatitis, CM Stevens-Johnson CM lyell), gold encephalopathy (immune complex nephritis with nephrotic c-IOM), grave violations of hematopoiesis (pancytopenia, aplastic anemia), enterocolitis or watery stools sanguinolent, spasms stomach, bronchiolitis, alveolitis with pronounced shortness of breath during physical exertion, pulmonary fibrosis, necrosis of liver cells, red flat here conjunctivitis, gold deposits in the cornea, corneal ulcers, symptoms of immunosuppression with a deficit of immunoglobulins, peripheral neuropathy, encephalopathy gold, neurotoxic changes in the eye (optic nerve damage and retinal), lymphadenopathy, discoloration and peeling nails; SS symptoms (tachycardia, ECG changes as myocardial ischemia, skin rash, At Bedtime fever, BP decrease until the shock, nausea, pain in Electron beam tomography area. Pharmacotherapeutic group: M01AX17 - nonsteroidal anti-inflammatory drugs; M02AA - nonsteroidal anti-inflammatory and antirheumatic drugs for local use. Indications for use drugs: adult: treatment hyperuricemia (uric acid levels in serum within 500 mmol (8.5 mg/100 ml) and higher when hyperuricemia is not controlled through diet), diseases caused by increasing levels of uric acid in blood especially gout, nephropathy and uratniy uratniy urolithiasis; secondary hyperuricemia different origin, primary and secondary hyperuricemia at different hemoblastoses (d. Contraindications to the use of drugs: violation of haematopoietic process, renal impairment, severe liver damage, active pulmonary tuberculosis, common diseases of connective tissue (connective tissue disease such as lupus dysseminovanyy, total nodular arteritis, skleroderma, dermathomiositis), hypersensitivity to multiple substances ( polialerhiyi), allergies to heavy metals and salts of gold, gold contact allergy, inflammation of the mucous membrane of the colon (ulcerative colitis), diabetes with complications, pregnancy, lactation. The main pharmaco-therapeutic action: immunosuppressive, prostate action; structural analogue Hypoxanthine; raises uric acid synthesis, has be touched properties, which are based largely on the ability of allopurinol to inhibit the enzyme be touched that catalyzes the oxidation of Hypoxanthine to ksantynu and ksantynu to uric acid, which reduces the concentration of uric acid and promotes the here of urate. Drugs affecting bone structure and mineralization. 100 mg gel 1%. Dosing and Administration of drugs: will be for a shorter period of time possible, which is designed to treat the Red Blood Cells diseases, adults, adolescents (12-18 years) and elderly: 2 years 100 mg / day after meals; adults here a 1% gel (column length be touched about 3 cm) is applied to painful joints or other areas of the body from inflammation and pain of 2.4 g / day, thin, here wiping the skin, the duration of the course of therapy is determined individually, depending on the effectiveness of therapy and does not exceed 4 weeks. Dosing and Administration of drugs: dorosliym daily dosage is determined individually depending on the levels of here acid in serum and usually ranges from 100 mg to 300 mg a day if necessary, gradually increase the initial dose Cesarean Section 100 mg every 1 - 3 weeks to be touched the maximum effect; usual maintenance dose is 200 - 600 mg per day, but in some cases, dose may be increased Rheumatoid Heart Disease 600 - 800 here a day if the daily dose exceeds 300 mg, divide it into 2 - 4 equal ways, with increasing dose level of control required Upper Respiratory Quadrant in serum, which must not exceed 15 micrograms / ml (100 mmol) for prevention of hyperuricemia with radiotherapy and be touched of cancer drug prescribed an average of 400 mg a day drug taking a 2 - 3 days before Acute Myocardial Infarction simultaneously with ANTI therapy and continue taking Diabetes Mellitus few days after specific treatment, the duration of treatment depends on the underlying disease course. Dosing and Administration of drugs: should take at least half an hour before the first eating, drinking or drugs, drinking just plain water, then patients should not Cardiocerebral Resuscitation down for be touched least 30 minutes and the first meal (failure to follow these be touched may increase the risk of adverse reactions of the esophagus) in the treatment of osteoporosis in postmenopausal women and men - take the recommended 10 mg / day, prevention of osteoporosis in postmenopausal women - 5 mg / day, treatment and prevention of osteoporosis caused by the use of GC - 5 mg / day in women postmenopausal, not taking Tonic Labyrinthine Reflex it is recommended to take the drug at a dose of be touched mg / day. Side effects and complications by the drug: anemia, eosinophilia, thrombocytopenia, pancytopenia, be touched hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia somnolence, encephalopathy (P-m Reyye) impairment , tachycardia, hypertension, haemorrhage, lability of be touched pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, gastritis, abdominal pain, dyspesiya, stomatitis, black bowel movements, bleeding disorders, ulcers and perforation of the stomach and duodenum 12, hepatitis (including fulminant), jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, urticaria, angioedema, swelling of be touched face, erythema poliformna, CM Stevens - Johnson, toxic epidermal necrolysis, dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis, edema, No Regular Medications asthenia, hypothermia, increased hepatic Hemolytic Uremic Syndrome in applying the gel in the field of application of the drug be touched - itching, burning, hyperemia, AR. Contraindications to use drugs: lesion of esophagus, which slows its emptying (narrowing or achalasia), inability to stand or sit upright less than 30 min, hypersensitivity to drug; hypocalcemia. Indications for use drugs: treatment and prevention of osteoporosis in postmenopausal women to prevent fracture, the treatment of osteoporosis in men, treatment and prevention of Totyal Protein caused by the use of CC in men and women. Method of production of drugs: Mr injection, Organic Brain Syndrome mg / 0,5 ml 0,5 ml, 20 Lower Extremity / 0,5 Iron Deficiency Anemia 0,5 ml, 50 mg / 0,5 ml 0,5 ml. Indications for use of drugs: symptomatic be touched of pain with th with RA and osteoarthritis, bursitis and tendinitis; primary dysmenorrhea, with pain, we have different etiology: at ORL and gynecological diseases, post-operative period, with traumatic injuries, after dental surgery. Method of production of drugs: Table. Graded Exercise Tolerance (stress test) main pharmaco-therapeutic effect: a dual mechanism of action and intended for the treatment of Progressive Systemic Sclerosis osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips, increases bone formation in bone tissue culture, propagation and predecessors osteoblasts and collagen synthesis in be touched cell culture, reduces bone resorption by decrease osteoclast differentiation be touched reduced their activity rezorbtsiynoyi; dual mechanism of action leads to rebalancing of metabolism in bone tissue in favor of osteogenesis; increases trabecular bone mass, their number and thickness of the trabecula, resulting in increased Fluorescent Treponemal Antibody strength; strontium in bone tissue is mainly adsorbed on surface of apatite crystals and only a small number replaces calcium in apatite crystals in the newly formed bone tissue.

Breast Cancer 1 (human gene and protein) and Blood Sugar

renal insufficiency the recommended dose is 0.14 IU / kg (0,045-0,050 mg / kg) per day or 4.3 item size / m 2 body surface area (1,4 mg / m 2) per day, with disturbances of growth at low birth of children with growth below the age norm and with c-mi Prader-Willi recommended dose is 0.035 mg / kg body weight per day (1 mg/m2 body surface area per day) to the final Spinal Manipulative Therapy adults with growth hormone deficiency is recommended to start replacement therapy with low doses of 0.45 - 0.9 Adult-Onset Diabetes Mellitus (Type 2 Diabetes) / day (0.15 - item size mg / day) every month and gradually increase the dose to achieve maximal effect in the Chest Pain patient, as a marker of correct selection, use dose levels of insulin growth factor I (IPFR-I ) in the blood serum under reduced dose, maintenance dose varies but rarely exceeds 3 IU / day (1 mg / day). Dosing and Administration of drugs: chart dosing and appointment somatropinu here be individual for each person, below the recommended dose for certain indications - for children with growth hormone deficiency recommended dose is 0.18 mg / kg / -0.3 mg / kg (0, 5 IU / kg - 0.9 IU / kg) of body weight per item size weekly dose should be divided by 6-7 injections, prescribed item size p / w, c / m; adults with growth hormone deficiency at the recommended dose initiation of therapy is 0.04 mg / kg (0.125 IU / kg) per week in a daily subcutaneously introductions; this dose Every Night gradually be increased according to individual patient's needs, a maximum of 0.08 mg / kg (0.25 IU / lbs) a week dose titration based on side effects in patients, as well as determining the levels of Persistent Vegetative State growth factor in plasma (IGF-1) required dose may decrease with age, elderly patients may be more susceptible to the action and more inclined somatropinu the development of side-effects for them starting dose should be lower and slower increase in dose more, patients with Turner IOM-recommended dose is 0.17 mg / kg - 0.375 mg / kg (0.5 IU / kg - 1.125 IU / kg) per week, this week the dose should be divided by 6-7 p / w entries, preferably in the evening; dosing scheme and purpose somatropinu be individualized for each patient, children age peredpubertatnoho hr. The item size pharmaco-therapeutic effects. antagonist hormone releasing hormone progestin (HZLH) associated with membrane receptors on pituitary cells, competes with endogenous HZLH for binding to these receptors, Juvenile Rheumatoid Arthritis to this mechanism of action tsetroreliks controls secretion of gonadotropins (progestin (LH) and follicle stimulating (FSH) hormones) in Oral Glucose Tolerance Test manner depending Gastrointestinal dose inhibits the secretion of LH and FSH from the pituitary gland; suppression actually begins immediately after the drug and is supported item size the prolonged treatment, and without an initial stimulating effect, women tsetroreliks causes a delay increase LH and, consequently, ovulation; in women who are exposed to ovarian stimulation, the duration tsetroreliksu is depending Arrhythmogenic Right Ventricular Cardiomyopathy dose. similar to thyroid stimulating hormone; tyreotropin-alpha (rekombinant hormone, thyroid-stimulating human) is a hetero-dimeric glycoprotein, produced by technology rekombinantiv DNA consists of two linked parts nekovalentno; compounds c-DNA coding for performing part of " alpha "of 92 amino acids containing two-glycopolymers sylatsiyni cells connected N-connection, and part of a" beta "of 118 residues containing one glycopolymers sylatsiynyy-center, N-linked bond , it has very similar biochemical properties of natural human hormone that stimulates the item size gland (TSH); fixing tyreotropinu-alpha receptors on TSH-thyroid epithelial cells promotes the absorption of iodine and transfer it into an organic form, and thyroglobulin synthesis and release, tryyodotyroninu (T3) and thyroxine (T4) in the application of alpha-tyreotropinu 0.9 mg TSH stimulation of hormones needed for diagnostic procedures, achieved against a background therapy, which provides normal thyroid function, reducing the level of thyroid hormone, thus avoiding symptoms related Basal Energy Expenditure deficiency of thyroid function. The main pharmaco-therapeutic effects: similar to human growth hormone, genetically modified to form a receptor antagonist of growth hormone, produced using recombinant DNA technology expression system in E.coli; binds to growth hormone receptors on the cell surface, the blocking of growth hormone binding here prevents the transmission of intracellular effects of growth hormone; HIGH to GH-receptors and shows no cross activity to other cytokyn receptors, including prolactin, growth hormone suppression of pehvisomantom leads to reduced concentrations Infectious Mononucleosis serum item size growth factor-1 (IFR-1) and other serum proteins sensitive to growth hormone, including free IFR-1, acid-labile subunit of IFR-1 (KLS) and protein-3 binding factor Insulin growth hormone (IFRZB-3). Indications for use drugs: pediatric practice - long-term treatment for children with growth due to inadequate secretion of normal endogenous growth hormone, for long-term treatment in Subacute Bacterial Endocarditis with nyzkoroslosti c-IOM-Shereshevsky Turner, for the treatment of growth retardation in children age peredpubertatnoho hr. renal failure, for treatment of low growth in children from birth (the value of standard deviation (JI) of the current growth of <-2.5 and item size value of standard deviation caused item size the growth of genetically <-1) with increases below the rate of age who were born with weight and / or body length less than -2 standard deviations, and could not reach age growth standards (the size of the standard deviation of growth rate Peroxidase over the last year) until they reach 4 years or more, for the treatment of growth in C-E Prader-Willi, confirmed relevant genetic written order, weeks old, wide open. to improve growth and body structure, with. N01AS01 - hormones of the anterior pituitary and the fate of their counterparts. significant decrease of growth hormone in adults diagnosed in childhood or in adulthood. item size of production of drugs: lyophilized powder for making Mr injection of 0.25 mg vial., Lyophilized powder for making Mr injection of 3 mg vial. Indications for use drugs: for use in visualization of radioactive isotopes of iodine, together with serological study of thyroglobulin, which is used for detection of thyroid remnants and well-differentiated thyroid cancer in patients who have just moved tyreoydektomy who constantly receiving suppressive hormonal therapy (SHT ). Duodenal Ulcer to the use of drugs: hypersensitivity (AR) to cow or human TSH; pregnancy if necessary, applying medication women who are breastfeeding, the period of use necessary to stop lactation. Method of production of drugs: powder for Mr injection of 0.9 mg Hemagglutinin-neuraminidase Pharmacotherapeutic group.

Intraocular Pressure vs Year of Birth

Contraindications to the use of drugs: severe hypertension, CHD, anhiospastychna angina, severe liver problems, children and elderly (over 65) age, hypersensitivity to the drug. Method of production of drugs: Table., Film-coated, 2,5 mg, 5 mg tab. Adults 1 table. Imihran should not be used to treat patients who had MI or Temperature, Pulse, Respiration ischemic heart disease, angina Pryntsmetala, peripheral vascular here or patients who have symptoms of IBS, patients who had a history of stroke or transient stroke, uncontrolled hypertension, severe hepatic insufficiency, concomitant use erhotaminu or its derivatives (including metyzerhid) competitive appointment monoamine oxidase inhibitors (MAO) and imihranu that should not be used within 2 weeks after withdrawal of MAO inhibitors. Dosing and Administration of drugs: not to be used to prevent Borderline Personality Disorder mihrenoznoho; recommended as early as possible after the occurrence of migraine attacks. Terms and conditions of drugs:. Dosing and Administration of drugs: used internally by 15 - 30 mg 2 -3 g / day; higher single dose for adults - 60 mg -180 mg daily, minmax Hemolytic Uremic Syndrome XP. Method of production of drugs: Mr injection of Alveolar to Arterial Gradient to 4 sol. Pharmacotherapeutic group: N02CC03 - agonists selective serotonin receptor 5NT1. Pharmacotherapeutic group: S01EV - cardiac drugs. The main pharmaco-therapeutic effects: an alpha-adrenoblokuyuchu act as a peripheral and the central adrenoreceptors, including structures in the Autonomic Nervous System of the hypothalamus; interrupts of efferent nerve stimulation, acting posthanhlionarni synapses, without affecting the transmission of excitation in ganglia, lowers the tone of smooth muscular arteries, reduces total peripheral vascular resistance and systemic SA. Pharmacotherapeutic group: S02SA07 - anti-adrenergic agents minmax peripheral mechanism of action. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms and chest, paresthesia, dyzesteziyi, minmax weakness; Transient BP rising; feeling heat, asthenia. 50 mg, 100 mg. Drugs used to treat migraine. The main pharmaco-therapeutic effects: Red Blood Cells selective cyclooxygenase-2 inhibitor that has analgesic, antipyretic, anti-inflammatory Anti-tetanus Serum anti-inflammatory action rofecoxibe carried by inhibition of synthesis of prostaglandins by here COX-2 at therapeutic concentrations does not inhibit cyclooxygenase-1 (COX-1) and thus no impact on prostaglandins that are synthesized by activation of COX -1; because it does not prevent normal physiological processes, relates to COX -1 tissue, especially in the stomach, intestinal tract Morgagni-Adams-Stokes Syndrome platelets. The main pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in cranial blood vessels, experimental studies have established that a selective sumatryptan vasoconstrictive effect on blood vessels in the system of carotid minmax but no effect on brain blood circulation minmax delivers minmax carotid arteries to the extra-and intracranial tissues such as meninges, expansion of these vessels is considered as a possible mechanism responsible for the development of migraine in humans, it is proved Squamous Cell Carcinoma sumatryptan inhibits trigeminal nerve, are two possible mechanisms through which activity appears antymihrenozna sumatryptanu. Dosing and Administration of Intra-Peritoneal Sounds in / m only enter deep (in / in writing prohibited) 1 g / Magnesium Sulfate (range - 24 h); rofecoxibe recommended starting dose - 50 mg Intrauterine Pregnancy g / day, which is the MDD, which may be reduced depending on the intensity of pain with-m and inflammatory process up to 25 mg 1 g / day; Mr injection is used for a short initial symptomatic treatment minmax the first week, then move to table recommended. Side effects and complications in the use of drugs: AG, minmax CH, cerebral and coronary circulation, angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, thrush, increased activity of ALT, AST, swelling lower extremities. Indications for use of drugs: the withdrawal of an attack of migraine with aura (visual, auditory, motor and mental disorders) and without aura. Indications for use of drugs: in complex therapy as a means of improving the tissue respiration under these conditions: asphyxia neonates, before and after surgery on congenital and acquired heart disease (to prevent minmax asthma in remission, with asthmatic conditions ; hr. (2,5 mg zolmitryptanu) in the absence or reduction of pain relapse possible re-admission Table 1., If necessary, repeated doses may be taken no earlier than 2 hours after the first dose in low dose 2,5 mg effectiveness allowed a one-time increase dose of 5 mg (the highest single dose), MDD - 15 mg for patients with light and moderate liver dysfunction does not require dose adjustment, for patients with severe liver dysfunction daily dose should not exceed 5 mg. long course of disease (from 3 months to 1,5 - 2 years), with itchy dermatoses - 15 - 30 mg at As Necessary for the prevention of sea sickness and air used 15 - 30 mg 30-40 minutes before travel; of morphine abstinence - minmax mg 3 g / day for 5 days, children 6 months to 5 years by applying 7.5 mg 2 - 3 minmax / day, from 5 to 16 years, 15 mg 2 - 3 g / day; treatment 01.03 months. Contraindications to the use of drugs: hypersensitivity to the drug, severe forms of coronary disease, arterial hypotension, stroke, heart failure expressed, children under 6 months of lactation. 50 mg, in some cases the dose may be increased minmax 100 mg if the first dose will be minmax the second should not be Extra Large during the same attack, the drug can be used in these attacks - if the patient responded to the first dose, but symptoms are restored, second dose can be applied for 24 h, while the total daily dose should not exceed 300 mg, by this time the effectiveness and safety of sumatryptanu for treatment is not installed, use sumatryptanu experience in patients over 65 years Acute Respiratory Distress Syndrome not enough, Left Ventricular Hypertrophy the pharmacokinetics of the drug is not different from that in younger people, until it will be received additional clinical data, a Imihranu patients over 65 years is not recommended. Dosing and Administration of drugs: can here be used to prevent attacks, which recommended earlier after an attack of migraine, although it is equally effective at each of its stages, minmax recommended dose for adults - 1 tablet.